4.7 Article

Predicting outcome of IV thrombolysis-treated ischemic stroke patients The DRAGON score

期刊

NEUROLOGY
卷 78, 期 6, 页码 427-432

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318245d2a9

关键词

-

资金

  1. Finnish Medical Foundation
  2. Boehringer Ingelheim
  3. Lundbeck, Inc.
  4. Orion Corporation
  5. Abbott
  6. AstraZeneca
  7. Biomedicum Helsinki Foundation
  8. Finnish-Norwegian Medical Foundation
  9. Emil Aaltonen Foundation
  10. Yrjo Jahnsson Foundation
  11. Maire Taponen Foundation
  12. Paivikki and Sakari Sohlberg Foundation
  13. Instrumentarium Science Foundation
  14. Sigrid Juselius Foundation
  15. Boston Scientific
  16. Bayer Schering Pharma
  17. Shire plc
  18. sanofi-aventis
  19. PhotoThera
  20. Swiss National Foundation
  21. Swiss Heart Foundation
  22. Neurobiological Technologies, Inc.
  23. Mitsubishi Tanabe Pharma Corporation
  24. PAION AG
  25. Forest Laboratories, Inc.
  26. Kathe-Zingg-Schwichtenberg-Fonds of the Swiss Academy of Medical Sciences
  27. Swiss National Funds
  28. Finnish Academy of Sciences
  29. European Union
  30. Biocentrum Finland
  31. Biocentrum Helsinki
  32. Liv och Halsa
  33. Helsinki University Central Hospital

向作者/读者索取更多资源

Objective: To develop a functional outcome prediction score, based on immediate pretreatment parameters, in ischemic stroke patients receiving IV alteplase. Methods: The derivation cohort consists of 1,319 ischemic stroke patients treated with IV alteplase at the Helsinki University Central Hospital, Helsinki, Finland. We evaluated the predictive value of parameters associated with the 3-month outcome and developed the score according to the magnitude of logistic regression coefficients. We assessed accuracy of the model with boot-strapping. External validation was performed in a cohort of 330 patients treated at the University Hospital Basel, Basel, Switzerland. We assessed the score performance with area under the receiver operating characteristic curve (AUC-ROC). Results: The DRAGON score (0-10 points) consists of (hyper) Dense cerebral artery sign/early infarct signs on admission CT scan (both = 2, either = 1, none = 0), prestroke modified Rankin Scale (mRS) score >1 (yes = 1), Age (>= 80 years = 2, 65-79 years = 1, <65 years = 0), Glucose level at baseline (>8 mmol/L [>144 mg/dL] = 1), Onset-to-treatment time (>90 minutes = 1), and baseline National Institutes of Health Stroke Scale score (>15 = 3, 10-15 = 2, 5-9 = 1, 0-4 = 0). AUC-ROC was 0.84 (0.80-0.87) in the derivation cohort and 0.80 (0.74-0.86) in the validation cohort. Proportions of patients with good outcome (mRS score 0-2) were 96%, 88%, 74%, and 0% for 0-1, 2, 3, and 8-10 points, respectively. Proportions of patients with miserable outcome (mRS score 5-6) were 0%, 2%, 5%, 70%, and 100% for 0-1, 2, 3, 8, and 9-10 points, respectively. External validation showed similar results. Conclusions: The DRAGON score is valid at our site and was reliable externally. It can support clinical decision-making, especially when invasive add-on strategies are considered. The score was not studied in patients with basilar artery occlusion. Further external validation is warranted. Neurology (R) 2012; 78: 427-432

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据